Literature DB >> 27272831

Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma.

Dirk Rades1, Antonio J Conde-Moreno2, Jon Cacicedo3, Barbara Šegedin4, Volker Rudat5, Steven E Schild6.   

Abstract

AIM: Malignant spinal cord compression (SCC) is treated with radiotherapy (RT). Additional neurosurgery has become more widely used since a trial showed a benefit for selected patients. Although lymphomas were excluded from that trial, neurosurgery is also increasingly being performed in these patients. This study investigated whether neurosurgery is actually required for this group. PATIENTS AND METHODS: Twenty-nine patients receiving RT alone for SCC from vertebral lymphoma were analyzed for motor function, walking ability, in-field recurrence and survival.
RESULTS: Overall response was 100% (72% improvement, 28% stable). At 1, 6 and 12 months after RT, 83%, 100% and 100% of patients were able to walk; 64%, 100%, and 100% of non-ambulatory patients regained their walking ability. Freedom from in-field recurrence was 100% at 6 and 12 months. Survival rates at 6 and 12 months were 79% and 75%.
CONCLUSION: RT alone resulted in excellent outcomes for SCC from lymphoma. These patients may not require surgery. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  ambulation; lymphoma; radiation therapy; recurrences; spinal cord compression; survival

Mesh:

Year:  2016        PMID: 27272831

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  [Clinical characterization and outcome of non-Hodgkin lymphoma presenting with initial spinal cord compression: a retrospective study of 25 patients].

Authors:  W W Tian; L Tian; W Zhao; W Wan; J J Gao; K Hu; X Y Ke
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

2.  Identifying patients with malignant spinal cord compression (MSCC) near end of life who can benefit from palliative radiotherapy.

Authors:  Dirk Rades; Barbara Segedin; Steven E Schild; Darejan Lomidze; Theo Veninga; Jon Cacicedo
Journal:  Radiat Oncol       Date:  2022-08-17       Impact factor: 4.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.